SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Danaher Corp/DE – ‘8-K’ for 3/31/20

On:  Wednesday, 4/1/20, at 7:18am ET   ·   For:  3/31/20   ·   Accession #:  313616-20-79   ·   File #:  1-08089

Previous ‘8-K’:  ‘8-K’ on 3/30/20 for 3/25/20   ·   Next:  ‘8-K’ on 4/8/20 for 4/3/20   ·   Latest:  ‘8-K’ on / for 4/23/24   ·   1 Reference:  By:  Danaher Corp./DE – ‘10-K’ on 2/25/21 for 12/31/20

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 4/01/20  Danaher Corp/DE                   8-K:2,9     3/31/20   15:2.6M

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     53K 
 2: EX-2.1      Ge Biophrma Purchase Agreement                      HTML    653K 
 3: EX-23.1     Consent of Kpmg LLP, Independent Auditors           HTML     11K 
 4: EX-99.1     Audited Financial Statements of Ge Biopharma        HTML    408K 
11: R1          Cover Document                                      HTML     84K 
15: XML         IDEA XML File -- Filing Summary                      XML     13K 
13: XML         XBRL Instance -- biopharma8-k_htm                    XML     54K 
10: EXCEL       IDEA Workbook of Financial Reports                  XLSX      7K 
 6: EX-101.CAL  XBRL Calculations -- dhr-20200331_cal                XML      7K 
 7: EX-101.DEF  XBRL Definitions -- dhr-20200331_def                 XML     54K 
 8: EX-101.LAB  XBRL Labels -- dhr-20200331_lab                      XML    124K 
 9: EX-101.PRE  XBRL Presentations -- dhr-20200331_pre               XML     59K 
 5: EX-101.SCH  XBRL Schema -- dhr-20200331                          XSD     23K 
12: JSON        XBRL Instance as JSON Data -- MetaLinks               19±    26K 
14: ZIP         XBRL Zipped Folder -- 0000313616-20-000079-xbrl      Zip    203K

‘8-K’   —   Current Report

This is an HTML Document rendered as filed.  [ Alternative Formats ]

 iX:   C:   C:   C: 
  Document  
 i false i 0000313616 0000313616 2020-03-31 2020-03-31 0000313616 dhr:A1.7SeniorNotesDue2024Member 2020-03-31 2020-03-31 0000313616 dhr:A2.5SeniorNotesDue2030Member 2020-03-31 2020-03-31 0000313616 dhr:A1.8SeniorNotesDue2049Member 2020-03-31 2020-03-31 0000313616 dhr:A1.2SeniorNotesDue2027Member 2020-03-31 2020-03-31 0000313616 dhr:A2.1SeniorNotesDue2026Member 2020-03-31 2020-03-31 0000313616 dhr:FloatingRateSeniorNotesDue2022Member 2020-03-31 2020-03-31 0000313616 dhr:A0.45SeniorNotesDue2028Member 2020-03-31 2020-03-31 0000313616 dhr:A1.35SeniorNotesDue2039Member 2020-03-31 2020-03-31 0000313616 dhr:A0.75SeniorNotesDue2031Member 2020-03-31 2020-03-31 0000313616 dhr:A0.2SeniorNotesDue2026Member 2020-03-31 2020-03-31 0000313616 dhr:A2.5SeniorNotesDue2025Member 2020-03-31 2020-03-31 0000313616 us-gaap:PreferredStockMember 2020-03-31 2020-03-31 0000313616 us-gaap:CommonStockMember 2020-03-31 2020-03-31 0000313616 dhr:A1.7SeniorNotesDue2022Member 2020-03-31 2020-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________
FORM  i 8-K
_____________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):  i March 31, 2020
_____________________________________________
dhrlogofor8ksa22.jpg
 i DANAHER CORPORATION
 
(Exact Name of Registrant as Specified in Its Charter)
 
_____________________________________________
 i Delaware
 
 i 001-08089
 
 i 59-1995548
(State or Other Jurisdiction of Incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
 
 
 
 i 2200 Pennsylvania Avenue, NW
 
 
 
 i 20037-1701
 i Suite 800W
 
 
 
 i Washington,
 i DC
 
 
 
(Address of Principal Executive Offices)
 
 
 
(Zip Code)
 i 202- i 828-0850
(Registrant’s Telephone Number, Including Area Code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
_____________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 i ☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 i ☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 i ☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 i ☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
 i Common stock, $0.01 par value
 i DHR
 i New York Stock Exchange
 i 4.75% Mandatory Convertible Preferred Stock, Series A, without par value
 i DHR.PRA
 i New York Stock Exchange
 i Floating Rate Senior Notes due 2022
 i DHR F 06/30/22
 i New York Stock Exchange
 i 1.700% Senior Notes due 2022
 i DHR 1.7 01/04/22
 i New York Stock Exchange
 i 1.700% Senior Notes due 2024
 i DHR 1.7 03/30/24
 i New York Stock Exchange
 i 2.500% Senior Notes due 2025
 i DHR 2.5 07/08/25
 i New York Stock Exchange
 i 0.200% Senior Notes due 2026
 i DHR 0.2 03/18/26
 i New York Stock Exchange
 i 2.100% Senior Notes due 2026
 i DHR 2.1 09/30/26
 i New York Stock Exchange
 i 1.200% Senior Notes due 2027
 i DHR 1.2 06/30/27
 i New York Stock Exchange
 i 0.450% Senior Notes due 2028
 i DHR 0.45 03/18/28
 i New York Stock Exchange
 i 2.500% Senior Notes due 2030
 i DHR 2.5 03/30/30
 i New York Stock Exchange
 i 0.750% Senior Notes due 2031
 i DHR 0.75 09/18/31
 i New York Stock Exchange
 i 1.350% Senior Notes due 2039
 i DHR 1.35 09/18/39
 i New York Stock Exchange
 i 1.800% Senior Notes due 2049
 i DHR 1.8 09/18/49
 i New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
 
 i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




ITEM 2.01    COMPLETION OF ACQUISITION OF ASSETS.
On March 31, 2020, pursuant to the equity and asset purchase agreement, dated as of February 25, 2019 and as subsequently amended and restated as of March 31, 2020 (the “Purchase Agreement”), by and between Danaher Corporation (“Danaher”) and General Electric Company (“GE”), Danaher completed the acquisition of the Biopharma business of the Life Sciences business of GE (the “Biopharma Business”) through the acquisition of certain assets and the assumption of certain liabilities, as well as the acquisition of the equity of certain subsidiaries of GE, for a cash purchase price of approximately $21.0 billion, subject to certain adjustments, and the assumption of approximately $0.4 billion of pension liabilities (the “Transaction”).
The foregoing description of the Transaction and the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement listed as Exhibit 2.1 hereto which is incorporated by reference into this Item 2.01.

ITEM 9.01    FINANCIAL STATEMENTS AND EXHIBITS.
(a)    Financial Statements of Business Acquired
The audited combined financial statements of the Biopharma Business as of and for the years ended December 31, 2019 and December 31, 2018 are filed as Exhibit 99.1 to this amendment and incorporated herein by this reference.
(b)    Pro Forma Financial Information
To be filed by amendment not later than 71 calendar days after the date this Current Report is required to be filed.
(c)    Exhibits
Exhibit
Number
 
Exhibit Description
2.1
 
First Amended and Restated Equity and Asset Purchase Agreement, dated as of March 31, 2020, by and between General Electric Company and Danaher Corporation
23.1
 
Consent of KPMG, independent registered accounting firm
99.1
 
Audited Combined Financial Statements of GE BioPharma as of and for the years ended December 31, 2019 and 2018
104
 
Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
DANAHER CORPORATION
 
 
By:
/s/ James F. O'Reilly
Name:
James F. O'Reilly
Title:
Vice President - Associate General Counsel and Secretary
Date: April 1, 2020


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:4/1/20
For Period end:3/31/208-K/A
12/31/1910-K,  11-K,  5,  SD
2/25/198-K
12/31/1810-K,  11-K,  5,  SD
 List all Filings 

1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/25/21  Danaher Corp./DE                  10-K       12/31/20  153:22M
↑Top
Filing Submission 0000313616-20-000079   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Fri., Apr. 26, 10:49:45.2pm ET